Frontiers in Plant Science (Dec 2020)

Stable Protein Sialylation in Physcomitrella

  • Lennard L. Bohlender,
  • Juliana Parsons,
  • Sebastian N. W. Hoernstein,
  • Christine Rempfer,
  • Christine Rempfer,
  • Natalia Ruiz-Molina,
  • Timo Lorenz,
  • Fernando Rodríguez Jahnke,
  • Fernando Rodríguez Jahnke,
  • Rudolf Figl,
  • Benjamin Fode,
  • Friedrich Altmann,
  • Ralf Reski,
  • Ralf Reski,
  • Ralf Reski,
  • Ralf Reski,
  • Eva L. Decker

DOI
https://doi.org/10.3389/fpls.2020.610032
Journal volume & issue
Vol. 11

Abstract

Read online

Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their N-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. Physcomitrium patens (Physcomitrella, moss) is able to perform highly homogeneous complex-type N-glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the β1,2-xylosyltransferase and α1,3-fucosyltransferase genes (Δxt/ft). Furthermore, Physcomitrella meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering. However, all plants, in contrast to mammals, lack the capability to perform N-glycan sialylation. Since sialic acids are a common terminal modification on human N-glycans, the property to perform N-glycan sialylation is highly desired within the plant-based biopharmaceutical sector. In this study, we present the successful achievement of protein N-glycan sialylation in stably transformed Physcomitrella. The sialylation ability was achieved in a Δxt/ft moss line by stable expression of seven mammalian coding sequences combined with targeted organelle-specific localization of the encoded enzymes responsible for the generation of β1,4-galactosylated acceptor N-glycans as well as the synthesis, activation, transport and transfer of sialic acid. Production of free (Neu5Ac) and activated (CMP-Neu5Ac) sialic acid was proven. The glycosidic anchor for the attachment of terminal sialic acid was generated by the introduction of a chimeric human β1,4-galactosyltransferase gene under the simultaneous knock-out of the gene encoding the endogenous β1,3-galactosyltransferase. Functional complex-type N-glycan sialylation was confirmed via mass spectrometric analysis of a stably co-expressed recombinant human protein.

Keywords